Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 12/2020

01-12-2020 | SARS-CoV-2 | Notes From The Field

AIDS Activism and Coronavirus Vaccine Challenge Trials

Authors: Nir Eyal, Perry N. Halkitis

Published in: AIDS and Behavior | Issue 12/2020

Login to get access

Excerpt

On May 6, 2020, the WHO Working Group for Guidance on Human Challenge Studies in COVID-19 released a report according to which well-designed challenge studies could accelerate COVID-19 vaccine development, and delineated 8 criteria which would suffice for them to remain ethical [1]. Rejecting this guidance the very next day, a joint statement by Global Advocacy for HIV Prevention (AVAC) and Treatment Action Group (TAG) declared:
The WHO Working Group has articulated important criteria for assessing a challenge study, but we believe that they left out the most important one: Until there is an approved treatment, a challenge trial with a potentially fatal and as-yet untreatable pathogen is unacceptable [2].
…
Literature
1.
WHO Working Group for Guidance on Human Challenge Studies in COVID-19. Key criteria for the ethical acceptability of COVID-19 human challenge studies. Geneva: WHO; 2020.
2.
AIDS Vaccine Advocacy Coalition (AVAC), Treatment Action Group (TAG). AVAC and TAG Statement on Ethical Conduct of SARS-CoV-2 Vaccine Challenge Studies. AVAC. Vol 20202020.
3.
Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis. 2020;221:1752.CrossRef
4.
Plotkin SA, Caplan A. Extraordinary diseases require extraordinary solutions. Vaccine. 2020;38:3987.CrossRef
5.
6.
Verity R, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20:669.CrossRef
7.
Lentine KL, Lam NN, Segev DL. Risks of living kidney donation: current state of knowledge on outcomes important to donors. Evid-Based Nephrol. 2019;14:597–608.
8.
9.
Emanuel EJ, et al. Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. Br Med J. 2015;350:3271.CrossRef
10.
Deeks SG, Lewin SR, Ross AL, et al. International AIDS society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22:839.CrossRef
11.
Eyal N. The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction. J Med Ethics. 2017;43:65–6.CrossRef
12.
Eyal N. How to keep high-risk studies ethical: classifying candidate solutions. J Med Ethics. 2017;43:74–7.CrossRef
13.
14.
The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington D.C.: Departement of Health, Education, and Welfare1979.
15.
Halkitis PN. The AIDS generation: stories of survival and resilience. New York: Oxford UP; 2013.CrossRef
16.
Halkitis PN, Krause KD, Vieira DL. Mental health, psychosocial challenges and resilience in older adults living with HIV. HIV Aging. 2017;42:187–203.CrossRef
17.
Kuritzkes DR. Hematopoietic stem cell transplantation for HIV cure. J Clin Invest. 2016;126(2):432–7.CrossRef
18.
Styczynski J, Tridello G, Koster L, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transpl. 2020;55(1):126–36.CrossRef
19.
Evans D. An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research. J Med Ethics. 2017;43:100.CrossRef
20.
Millum JR, Bromwich D. Disclosure and consent to medical research participation. J Moral Philos. 2013;10(4):195–21919.
21.
Eyal N. Informed consent. In: Zalta EN, editor. Stanford encyclopedia of philosophy. Palo Alto: Stanford University; 2019.
22.
23.
Krieger LM. Coronavirus: would you volunteer to be exposed? These Stanford grads did. Mercury News. 2020.
24.
25.
26.
Brown R, Evans NG. The social value of candidate HIV cures: actualism versus possibilism. J Med Ethics. 2017;43(2):118–23.CrossRef
27.
Brown R, Deeks S, Eyal N. Maximizing the global health impact of future HIV cure-related interventions through advance planning. J Virus Erad. 2018;4(3):182.CrossRef
28.
29.
Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:e314–e316316.CrossRef
30.
Lodge W, Kuchukhidze S. COVID-19, HIV, and migrant workers: the double burden of the two viruses. AIDS Patient Care STDs. 2020;34:249.CrossRef
31.
Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020;18:1–6.
32.
Paintsil E. COVID-19 threatens health systems in sub-Saharan Africa: the eye of the crocodile. J Clin Investig. 2020;130(6):2741–4.CrossRef
33.
Hargreaves J, Davey C, Auerbach J, et al. Three lessons for the COVID-19 response from pandemic HIV. Lancet. 2020;7:2309–e2311.
34.
Laurence J. Why aren't people living with HIV at higher risk for developing severe coronavirus disease 2019 (COVID-19)? AIDS Patient Care STDs. 2020;34:247.CrossRef
35.
36.
37.
38.
39.
Hogan AB, Jewell B, Sherrard-Smith E, et al. The potential impact of the COVID-19 epidemic on HIV, TB and malaria in low- and middle-income countries. 2020.
Metadata
Title
AIDS Activism and Coronavirus Vaccine Challenge Trials
Authors
Nir Eyal
Perry N. Halkitis
Publication date
01-12-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 12/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02953-8

Other articles of this Issue 12/2020

AIDS and Behavior 12/2020 Go to the issue

Original Paper

Individual and Social Network Structure Characteristics Associated with Peer Change Agent Engagement and Impact in a PrEP Intervention

Original Paper

Internalized HIV Stigma and Pain among Women with HIV in the United States: The Mediating Role of Depressive Symptoms

Notes From The Field

Applying the Popular Opinion Leader Intervention for HIV to COVID-19

Original Paper

Improvements in Retention in Care and HIV Viral Suppression Among Persons with HIV and Comorbid Mental Health Conditions: Patient-Centered HIV Care Model

Original Paper

Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

Substantive Review

Systematic Review of Interventions to Reduce HIV Risk Among Men Who Purchase Sex in Low- and Middle-Income Countries: Outcomes, Lessons Learned, and Opportunities for Future Interventions
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits